[大肠杆菌或欧文氏菌天冬酰胺酶与皮质激素疗法对儿童急性淋巴细胞白血病诱导期纤维蛋白原浓度的影响] - Suppr | 超能文献

[Effect of E coli or Erwinia asparaginase and corticotherapy on fibrinogen concentration in induction of acute lymphoblastic leukemia in children].

作者信息

Astruc D, Nowak V, Grunebaum L, Wiesel M L, Cazenave J P, Babin-Boilletot A, Lutz P

出版信息

Arch Pediatr. 1994 Jun;1(6):617-8.

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

[Effect of E coli or Erwinia asparaginase and corticotherapy on fibrinogen concentration in induction of acute lymphoblastic leukemia in children].[大肠杆菌或欧文氏菌天冬酰胺酶与皮质激素疗法对儿童急性淋巴细胞白血病诱导期纤维蛋白原浓度的影响]

Arch Pediatr. 1994 Jun;1(6):617-8.

2

Effect of glucocorticoids, E. coli- and Erwinia L-asparaginase on hemostatic proteins in children with acute lymphoblastic leukemia.糖皮质激素、大肠杆菌和欧文氏菌L-天冬酰胺酶对急性淋巴细胞白血病患儿止血蛋白的影响。

Klin Padiatr. 1999 Jul-Aug;211(4):205-10. doi: 10.1055/s-2008-1043789.

3

Erwinia- and E. coli-derived L-asparaginase have similar effects on hemostasis. Pilot study in 10 patients with acute lymphoblastic leukemia.欧文氏菌属和大肠杆菌衍生的L-天冬酰胺酶对止血有相似作用。对10例急性淋巴细胞白血病患者的初步研究。

Haematologica. 1993 Nov-Dec;78(6 Suppl 2):57-60.

4

Minimal residual disease (MRD) measurement as a tool to compare the efficacy of chemotherapeutic drug regimens using Escherichia Coli-asparaginase or Erwinia-asparaginase in childhood acute lymphoblastic leukemia (ALL).微小残留病（MRD）检测作为一种工具，用于比较在儿童急性淋巴细胞白血病（ALL）中使用大肠杆菌天冬酰胺酶或欧文氏菌天冬酰胺酶的化疗药物方案的疗效。

Pediatr Blood Cancer. 2006 Sep;47(3):299-304. doi: 10.1002/pbc.20684.

5

Minimal effects of E. coli and Erwinia asparaginase on the coagulation system in childhood acute lymphoblastic leukemia: a randomized study.大肠杆菌和欧文氏菌天冬酰胺酶对儿童急性淋巴细胞白血病凝血系统的影响极小：一项随机研究。

Med Pediatr Oncol. 1994;23(4):335-43. doi: 10.1002/mpo.2950230404.

6

Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study.成人急性淋巴细胞白血病或淋巴细胞淋巴瘤患者使用L-天冬酰胺酶诱导化疗期间抗凝血酶和纤维蛋白原水平的变化。支持性凝血治疗的应用及临床结局：CAPELAL研究

Haematologica. 2008 Oct;93(10):1488-94. doi: 10.3324/haematol.12948. Epub 2008 Aug 25.

7

Pharmacoanalytical assays of Erwinia asparaginase (erwinase) and pharmacokinetic results in high-risk acute lymphoblastic leukemia (HR ALL) patients: simulations of erwinase population PK-PD models.欧文氏菌天冬酰胺酶（欧文酶）的药物分析测定及高危急性淋巴细胞白血病（HR ALL）患者的药代动力学结果：欧文酶群体药代动力学-药效学模型的模拟

Anticancer Res. 2007 Jul-Aug;27(4C):2561-72.

8

Pharmacokinetics and drug monitoring of L-asparaginase treatment.L-天冬酰胺酶治疗的药代动力学与药物监测

Int J Clin Pharmacol Ther. 1997 Mar;35(3):96-8.

9

[The feasibility of Erwinia asparaginase for pediatric patients who developed an allergic reaction to E.coli asparaginase during treatment of acute lymphoblastic leukemia].[欧文氏菌天冬酰胺酶用于在急性淋巴细胞白血病治疗期间对大肠杆菌天冬酰胺酶发生过敏反应的儿科患者的可行性]

Rinsho Ketsueki. 2013 Apr;54(4):370-7.

10

Thrombotic effects of asparaginase in two acute lymphoblastic leukemia protocols (NOPHO ALL-1992 versus NOPHO ALL-2000): a single-institution study.两种急性淋巴细胞白血病治疗方案（NOPHO ALL - 1992与NOPHO ALL - 2000）中天冬酰胺酶的血栓形成作用：一项单机构研究

Pediatr Hematol Oncol. 2006 Apr-May;23(3):207-16. doi: 10.1080/08880010500506701.